Latest:
Dr. Angiolillo on the Toxicity Profile of Traditional Treatment in Pediatric B-ALL
Anne Angiolillo, MD, discusses the adverse effects that are associated with traditional treatment in pediatric B-cell acute lymphoblastic leukemia.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David Swoboda, MD
David Swoboda, MD, is the clinical director of leukemia at Tampa General Hospital Cancer Institute and an assistant professor at the University of South Florida Morsani College of Medicine in Tampa.
Latest:
Dr Swoboda on the Role of TKIs in Chronic Myeloid Leukemia
David M. Swoboda, MD, discusses the roles of available TKIs for the treatment of patients with chronic myeloid leukemia.
Swetha Kambhampati, MD
Latest:
Dr Kambhampati on the Rationale For Evaluating Real-World Outcomes With Brexu-Cel in MCL
Swetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.
B. Hilda Ye, PhD
Latest:
Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic Features
Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.
Donna Catamero, ANP-BC OCN, CCRC
Donna Catamero, ANP-BC OCN, CCRC is Associate Director of Myeloma Research at Icahn School of Medicine at Mount Sinai Hospital.
Latest:
Catamero on Challenges of Community-Based Administration of Bispecifics and CAR T-Cell Therapy in Myeloma
Donna Catamero, ANP-BC, OCN, CCRC, discusses the challenges community-based clinicians face in delivering bispecific antibodies and CAR T-cell therapy for multiple myeloma.
Tim Eisen, MB BChir, PhD
Latest:
How Academia and Industry Intersect to Improve Oncology Research and Patient Care: With D. Ross Camidge, MD, PhD; and Tim Eisen, MB BChir, PhD
Drs Camidge and Eisen discuss Dr Eisen's dual career in academia and industry, the importance of aligning academic and clinical strengths, and how industry experience can enhance drug development.